immatics raises EUR54m to advance clinical therapeutic cancer vaccine portfolio
immatics biotechnologies, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, has raised EUR53.8m in a series C financing round. The new funds will allow the company to finance the ongoing development of immatics’ existing pipeline of advanced therapeutic cancer vaccine candidates. In particular, it allows the

